RIGL— RIGEL PHARMACEUTICALS INC

MaterialsBiotechnology$785M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$294.3M-99.8%	$179.28B+53.4%	$116.88B-2.8%	$120.24B
Cost of product sales	$19.6M-99.9%	$18.65B+162.3%	$7.11B+306.5%	$1.75B
Research and development	$33.3M-99.9%	$23.38B-4.7%	$24.52B-59.3%	$60.27B
Selling, general and administrative	$115.9M-99.9%	$113.06B+6.9%	$105.74B-6.0%	$112.45B
Total costs and expenses	$168.8M-99.9%	$155.09B+12.9%	$137.37B-21.9%	$175.79B
Income (loss) from operations	$125.5M-99.5%	$24.19B+218.1%	-$20.49B+63.1%	-$55.55B
Interest income	$3.7M-99.8%	$2.09B-7.9%	$2.27B+232.2%	$684.0M
Interest expense	-$7.3M+99.9%	-$7.92B-15.2%	-$6.87B-85.4%	-$3.71B
Income (loss) before income taxes	$121.8M-99.3%	$18.37B+173.2%	-$25.09B+57.2%	-$58.57B
(Benefit from) provision for income taxes	-$245.2M-127.8%	$881.0M+45.6%	$605.0M	—
Net income (loss)	$367.0M-97.9%	$17.48B+169.7%	-$25.09B+57.2%	-$58.57B
Basic (in dollars per share)	$20.40+1960.6%	$0.99+807.1%	-$0.14+58.8%	-$0.34
Diluted (in dollars per share)	$19.48+1867.7%	$0.99+807.1%	-$0.14+58.8%	-$0.34
Basic (in shares)	18.0M+2.3%	17.6M+10001.9%	174K+0.9%	172K
Diluted (in shares)	18.8M+6.5%	17.7M+10063.9%	174K+0.9%	172K
Product sales, net
Contract revenues from collaborations
Government contracts

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.